A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3116-3123

  Kong, Feng Ming Spring ^a   Frey, Kirk A ^a   Quint, Leslie E ^a   Ten Haken, Randall K ^a   Hayman, James A ^a   Kessler, Marc ^a   Chetty, Indrin J ^a   Normolle, Daniel ^a   Eisbruch, Avraham ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; DIAGNOSTIC AGENT;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; TISSUE METABOLISM; TUMOR VOLUME; AGED; COMPUTER ASSISTED RADIOTHERAPY; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; RADIATION RESPONSE; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROBABILITY; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547681369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3747     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507, 2006
3. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
4. Mac Manus MP, Hicks RJ, Matthews JP, et al: Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49:95-108, 2005
5. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
6. Eschmann SM, Friedel G, Paulsen F, et al: Repeat (18)F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55:165-171, 2007
7. Mac Manus MP, Hicks RJ, Matthews JP, et al: Positron emission tomography is superior to CT scanning for response assessment after radical radiotherapy/chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285-1292, 2003
8. Yamamoto Y, Nishiyama Y, Monden T, et al: Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33:140-147, 2006
9. Weber WA, Petersen V, Schmidt B, et al: Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651-2657, 2003
10. Choi NC, Fischman AJ, Niemierko A, et al: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:1024-1035, 2002
11. Eschmann SM, Friedel G, Paulsen F, et al: (18)F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:463-471, 2007
12. Cerfolio RJ, Bryant AS, Winokur TS: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78:1903-1909, 2004; discussion 1909
13. Pöttgen C, Levegrun S, Theegarten D, et al: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12:97-106, 2006
14. Hellwig D, Graeter TP, Ukena D, et al: Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 128:892-899, 2004
15. Hicks RJ, Mac Manus MP, Matthews JP, et al: Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60:412-418, 2004
16. Shankar LK, Hoffman JM, Bacharach S, et al: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-1066, 2006
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Dose Schwarz J, Bader M, Jenicke L, et al: Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46:1144-1150, 2005
19. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
20. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
21. Brun E, Ohlsson T, Erlandsson K, et al: Early prediction of treatment outcome in head and neck cancer with 2-18-FDG PET. Acta Oncol 36:741-747, 1997
22. Hautzel H, Muller-Gartner HW: Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38:1384-1386, 1997
23. Erdi YE, Macapinlac H, Rosenzweig KE, et al: Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27:861-866, 2000
24. van Baardwijk A, Bosmans G, Dekker A, et al: Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy: A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82:145-152, 2007
25. Feng M, Kong FM, Frey KA, et al: The use of FDG-PET to assess tumor response during radiotherapy for non-small cell lung cancer and its potential impact on normal tissue sparing or tumor dose escalation. Presented at Annual Conference on Radiation Society North America, Chicago, IL, December 1, 2005
26. Kong FM, Ten Haken RK, Schipper MJ, et al: High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63:324-333, 2005